One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Verastem logo
Verastem VSTM
$ 9.21 -1.39%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Verastem Income Statement 2025-2010 | VSTM

Brief overview of financial results at Verastem

The figures are compared over a five-year interval. The revenue attributed to Verastem moved from 88.5 million dollars to 30.9 million dollars between the two endpoints. The cumulative result was −65.1%, corresponding to roughly −19% per year. Revenue ended the period on a sustained downward trend.

EBITDA changed from −$48.8 million to −$170 million (−248.4%). The operating result developed less favorably than sales. EBITDA margin was −55.2% at the start and −550.2% at the end. The business retained less EBITDA from each unit of revenue.

Net income moved from −$67.7 million at the start to −$209 million at the end. The loss widened and increased the financial risk.

Financial takeaway

The current trajectory does not yet confirm a sustainable recovery. Caution is warranted because of weak sales momentum, pressure on operating profitability and a narrow EBITDA buffer. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Verastem

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Market Cap

404 M 208 M 232 M 6.94 M 29.8 M 327 M 133 M 209 M 138 M 46.6 M 43.1 M 188 M 291 M 187 M 14.8 M -

Shares

69.3 M 35.7 M 22.1 M 16.1 M 14.5 M 153 M 74.6 M 65 M 38.4 M 37 M 35.9 M 25.8 M 22.7 M 18.8 M 1.3 M 850 K

Historical Prices

5.83 5.83 10.5 0.43 2.05 2.13 1.34 3.36 3.07 1.12 1.86 9.14 11.4 8.79 - -

Net Income

-209 M -131 M -87.4 M -73.8 M -71.2 M -67.7 M -149 M -72.4 M -67.8 M -36.4 M -57.9 M -53.4 M -41.2 M -32 M -13.7 M -784 K

Revenue

30.9 M 10 M - 2.6 M 2.05 M 88.5 M 17.5 M 26.7 M - - - - - - - -

Cost of Revenue

- - - - - - - 165 K - - - - - - - -

Gross Profit

- - - - - - 14.6 M 26.6 M - - - - - - - -

Operating Income

-170 M -115 M -92.1 M -72.9 M -61.4 M -49.4 M -132 M -94.8 M -67.8 M -37 M -58.2 M -53.6 M -41.4 M -32.2 M -13.7 M -784 K

Interest Expense

1.14 M 4.56 M 4.14 M 2.14 M 9.97 M 15.8 M 20.6 M 5.81 M 559 K - - - - - - -

EBITDA

-170 M -115 M -92 M -72.8 M -61.2 M -48.8 M -130 M -94.4 M -67.2 M -36.3 M -57.4 M -53.2 M -41.2 M -32 M -13.6 M -784 K

Operating Expenses

- - - - - - 147 M 121 M 67.8 M 37 M 58.2 M 53.6 M 41.4 M 32.2 M - 784 K

General and Administrative Expenses

81.1 M 43.6 M 30.7 M 25 M 24.1 M 62.8 M 101 M 77.3 M 21.4 M 17.2 M 17.6 M 18.2 M 15.5 M 10.5 M - 384 K

All numbers in USD currency

Quarterly Income Statement Verastem

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

100 M 98.3 M 73.2 M 66.1 M 54.2 M 44.8 M 40.3 M 26.9 M 26.8 M 25.3 M 26.8 M 17.7 M 16.7 M 16.7 M 16.4 M 15.5 M 186 M 185 M 180 M 172 M 172 M 170 M 170 M 165 M 108 M 76.3 M 74.2 M 73.9 M 73.9 M 73.8 M 73.6 M 61.3 M 50.8 M 42 M 37.6 M 37 M 37 M 37 M 37 M 37 M 37 M 36.9 M 36.9 M 36.5 M 33.3 M 26.2 M 25.8 M 25.7 M 25.5 M 25.3 M 24.1 M 20.7 M 20.5 M 20.3 M 20.2 M 19.9 M 14.7 M 1.5 M 1.36 M 1.22 M 1.09 M

Net Income

-34.7 M -36.6 M -98.5 M -25.9 M -52.1 M - -24 M -8.26 M -33.9 M - -20 M -24.3 M -15.7 M - -18.1 M -22 M -17 M - -22.8 M -16.9 M -15 M -19.9 M 13.1 M -23 M -38 M -38.8 M -30.1 M -42.2 M -38.1 M -11.3 M -21.7 M -18.4 M -21 M -18.2 M -23.1 M -13.4 M -13 M -11.7 M -7.92 M -8.57 M -8.29 M -11.9 M -15.4 M -15.4 M -15.2 M -13.9 M -13.3 M -13 M -13.1 M -11.3 M -10.6 M -10.2 M -9.04 M -7.92 M -10.4 M -6.82 M -6.87 M -6 M -4.05 M -2.48 M -1.15 M

Revenue

40.1 M 18.7 M 11.2 M 2.14 M - - - 10 M - - - - - - 2.6 M 2.6 M 2.6 M - 2 K 500 K 1.01 M 506 K 78.6 M 4.31 M 5.06 M 3.62 M 9.03 M 3.14 M 1.67 M 1.21 M 15.5 M 10 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - 31.2 M - - - - - 158 K 116 K 49 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-32.7 M -44.9 M -40.7 M -43.8 M -44.2 M - -37 M -18.3 M -28.1 M - -21.3 M -20.3 M -19.3 M - -17.7 M -21.4 M -17 M - -14.8 M -15.9 M -14.1 M -16.8 M 15 M -21.3 M -26.4 M -33.3 M -26.1 M -38.3 M -34.7 M -34.3 M -21.6 M -18.2 M -20.8 M -18.1 M -23.1 M -13.5 M -13.1 M -11.8 M -8.06 M -8.71 M -8.43 M -12 M -15.5 M -15.5 M -15.2 M -14 M -13.4 M -13.1 M -13.1 M -11.4 M -10.6 M -10.3 M -9.08 M -7.98 M -10.4 M -6.9 M -6.93 M -6.02 M -4.05 M -2.48 M -1.15 M

Interest Expense

360 K 382 K 319 K 212 K 192 K - 1.15 M 1.14 M 1.13 M - 1.13 M 1.12 M 769 K - 717 K 640 K 56 K - 7.98 M 1.01 M 975 K 1.35 M 1.9 M 1.87 M 10.7 M 5.45 M 5.04 M 5.18 M 4.93 M 3.95 M 862 K 516 K 480 K 328 K 110 K 109 K 12 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-32.7 M -44.9 M - - -44.2 M - - - -28.1 M - - - -19.3 M - -17.6 M -21.3 M -17 M - -14.7 M -15.8 M -14 M -16.8 M 15.5 M -21.1 M -26.3 M -33.3 M -25.8 M -38 M -34.6 M -33.9 M -20.7 M -17.4 M -20.6 M -18.1 M -22.7 M -13.2 M -13 M -11.8 M -7.54 M -8.35 M -8.25 M -12 M -15 M -15.1 M -15.1 M -14 M -13.1 M -12.9 M -13.1 M -11.4 M -10.5 M -10.2 M -9.02 M -7.98 M -10.3 M -6.8 M -6.88 M -6.02 M -4 M -2.47 M -1.15 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 36.3 M 35.5 M 37.1 M 28.2 M 20.8 M 18.1 M 23.1 M 13.5 M 13.1 M 11.8 M 8.06 M 8.71 M 8.43 M 12 M 15.5 M 15.5 M 15.2 M 14 M 13.4 M 13.1 M 13.1 M 11.4 M 10.6 M 10.3 M 9.08 M 7.98 M 10.4 M 6.9 M 6.93 M 6.02 M 4.05 M 2.48 M 1.15 M

General and Administrative Expenses

8.54 M 22.3 M 21 M 20.7 M 15 M - 12.3 M 10.2 M 10.4 M - 7.36 M 7.4 M 7.33 M - 6.42 M 6.51 M 5.93 M - 5.52 M 6.71 M 6.22 M 7.1 M 20.6 M 15.4 M 19.6 M 23.7 M 22.2 M 29.3 M 26 M 26.2 M 25.4 M 15.8 M 9.83 M 6.8 M 5.39 M 4.42 M 4.76 M 4.91 M 3.84 M 4.22 M 4.26 M 4.27 M 4.23 M 4.42 M 4.71 M 4.31 M 4.34 M 4.78 M 4.72 M 3.59 M 3.86 M 4.24 M 3.78 M 3.88 M 2.3 M 2.21 M 2.12 M 1.62 M 965 K 759 K 471 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company Verastem (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
- - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
- - $ 5.18 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
- - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
- 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
- - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
- 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
- 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
- - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
- - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
- - $ 528 M usaUSA
Galecto Galecto
GLTO
- - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
- -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
- - $ 18.8 M usaUSA
IMARA IMARA
IMRA
- 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
- - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
- -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
- - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
- - $ 63.4 M usaUSA